Abstract
A highly selective thrombin inhibitor, MD 805 was evaluated as an anticoagulant for hemobialysis.
In in vitro study, MD 805 inhibited coagulation system without any effect on platelet function. MD 805 prologed clotting time enough to prevent blood coagulation in extracorporeal circulation with no adverse effects during hemodialysis. Transiently decreased platelet counts in early phase of hemodialysis returned to initial levels within one hour from the start of hemodialysis.
Fibringen was not changed significantly by hemodialysis.
Half life of MD 805 was about 30 minutes.
In conclusion, MD 805 is considered to be a usefull anticoagulant for hemodialysis.
